BridgeBio Pharma said on Monday its experimental drug for a rare muscle disorder, which currently has no approved treatments, showed improvements in motor and lung function in a late-stage trial, ...

BridgeBio Pharma Inc.’s drug to treat a devastating muscle-wasting disorder met its goal in a late-stage trial, paving the ...

BridgeBio Pharma said on Monday its experimental drug for a rare muscle disorder, which currently has no approved treatments, showed improvements in motor and lung function in a late-stage trial. The ...

New interim data from a Phase III trial puts the company on track to file for FDA approval next year in an indication that ...

Muscle dysmorphia is increasing in Europe as social media and gym culture drive compulsive exercise and steroid use, ...

Swiss pharmaceutical giant Novartis has announced a definitive agreement to acquire U.S.-based biotech firm Avidity ...

These organ models could help scientists study diseases such as muscular dystrophy and space-induced muscle atrophy. They may ...

Autoimmune neuromuscular diseases may sound complex, but understanding them is the first step to getting the right care and ...

According to the agreement, Avidity ( NASDAQ: RNA) shareholders will receive $72 a share in cash, a 46% premium to Friday’s ...

His parents Stephen and Jenny have asked Sheffield Children's NHS Foundation Trust to approve the use of drug givinostat, ...

If cancer is a disease of overabundance, where cells divide without restraint and tumors grow despite the body's best interests, then degenerative diseases are disorders of deprivation. When ...

Human health is the Achilles heel of space travel. Researchers at ETH Zurich have now succeeded in printing complex muscle ...